Does Cyclobenzaprine Make You Constipated?

Constipation is one of the most frequently reported side effects of cyclobenzaprine. A pooled analysis of clinical trials for the extended-release formulation lists constipation among the top adverse events, alongside dry mouth, dizziness, headache, and drowsiness.¹ If you have just started taking cyclobenzaprine and your gut has slowed to a crawl, the drug is very likely the reason, and you are far from the only one experiencing it.

Why Cyclobenzaprine Slows the Gut

Cyclobenzaprine is classified as a skeletal muscle relaxant, but its molecular structure closely resembles that of older tricyclic antidepressants, particularly amitriptyline.² That family resemblance is more than cosmetic. Like tricyclic antidepressants, cyclobenzaprine blocks acetylcholine receptors throughout the body. In the brain, that contributes to the drowsiness most people notice. In the digestive tract, it means the muscles that normally push food along lose some of their signaling. Everything slows down, water gets reabsorbed from stool that sits around too long, and the result is harder, less frequent bowel movements.

This anticholinergic effect is essentially baked into the drug’s chemistry. The same receptor-blocking activity that relaxes skeletal muscle also dampens smooth muscle activity in the intestines. Dry mouth, another classic anticholinergic complaint, tends to travel with constipation for the same reason: both are driven by the same mechanism, just in different tissues.

How Common the Problem Is

Constipation consistently shows up in the top tier of cyclobenzaprine’s side-effect profile across different types of studies. In a large pharmacovigilance analysis of the FDA’s adverse-event reporting system, constipation appeared among the 30 most frequently reported events associated with cyclobenzaprine, with a reporting odds ratio of about 1.7, meaning it was reported roughly 70% more often than you would expect by chance across the entire database.³ Pooled clinical trial data for the extended-release formulation tells a similar story, consistently placing constipation among the handful of most common adverse events.¹

One thing worth keeping in mind with adverse-event databases is that they capture voluntary reports, not controlled observations. That means the absolute numbers can be misleading in either direction. Mild constipation often goes unreported because people just deal with it, which would undercount the problem. On the other hand, people who already tend toward constipation may be more likely to flag it. The clinical trial data gives a cleaner picture, and it confirms constipation is a real and common effect rather than a statistical artifact.

The Dose Connection

Not all cyclobenzaprine prescriptions are equal when it comes to gut side effects. The drug is available in both immediate-release and extended-release forms, and the dose range spans from 5 mg up to 30 mg daily depending on the condition being treated. Higher doses predictably produce more anticholinergic side effects. A systematic review of interventions for fibromyalgia found that adverse effects were highest in the group receiving 30 mg of cyclobenzaprine.⁴

This is one area where the evidence actually offers a practical lever. If constipation is making you miserable, it is worth asking your prescriber whether a lower dose might still manage your muscle spasm or pain while easing up on the gut. Many clinicians now start with the lowest effective dose (often 5 mg) and increase only if needed, partly because of how dose-dependent the anticholinergic burden is. The extended-release formulation was designed in part to deliver the drug more gradually, which can blunt the peak blood level and sometimes reduce the intensity of side effects, though constipation can still occur at any dose.

A Surprising Sex Difference in Reporting

One of the more unusual findings to come out of the FDA adverse-event analysis is that constipation associated with cyclobenzaprine was almost exclusively reported in males. In the subgroup breakdown, constipation met positive signal criteria only in male patients, while dry mouth, by contrast, met those criteria only in female patients.³

This does not necessarily mean women taking cyclobenzaprine never get constipated. Pharmacovigilance data reflects who reports what, and there are well-known differences in how men and women describe and report drug side effects. Men may be more likely to report constipation explicitly, while women may describe it as part of a broader cluster of abdominal complaints, or they may already be managing preexisting constipation with over-the-counter remedies and not think to report it as drug-related. Still, the pattern is striking enough to have been flagged, and it is consistent with some broader pharmacological research suggesting that sex hormones can influence how anticholinergic drugs affect gut motility. If you are male and noticing significant slowing of your bowel after starting cyclobenzaprine, you may be part of a particularly susceptible group.

How Cyclobenzaprine Compares to Other Muscle Relaxants

If constipation is your main concern, not all muscle relaxants carry the same risk. Cyclobenzaprine’s anticholinergic profile is notably heavier than that of methocarbamol, one of the most commonly used alternatives. In a study comparing the two drugs in hospitalized patients, roughly 14% of those receiving cyclobenzaprine experienced potential anticholinergic adverse events, compared with about 11% of those on methocarbamol.⁵ That gap is modest in percentage terms, but the types of anticholinergic events differ: cyclobenzaprine is more likely to cause constipation, urinary retention, and dry mouth because of its tricyclic-like structure.

Other muscle relaxants work through entirely different mechanisms and sidestep the anticholinergic problem almost entirely. Baclofen, for example, acts on GABA receptors in the spinal cord rather than blocking acetylcholine. It has its own side effects, mainly drowsiness and dizziness, but constipation is not a hallmark complaint. Tizanidine, another common option, works as an alpha-2 adrenergic agonist. It can cause dry mouth and drowsiness, and while some people report mild constipation, it is less consistently linked to it than cyclobenzaprine is. The broader point is that cyclobenzaprine’s constipation problem is not a universal muscle-relaxant side effect. It is specific to cyclobenzaprine’s chemical heritage as a tricyclic analog.

Who Faces the Highest Risk

Some people are more vulnerable to cyclobenzaprine-induced constipation than others, and a few risk factors are worth flagging.

Older adults: Anticholinergic sensitivity increases with age. The same dose that a 30-year-old tolerates easily can cause significant constipation, urinary retention, or confusion in someone over 65. Many geriatric prescribing guidelines specifically flag cyclobenzaprine as a drug to avoid in older patients because of this amplified anticholinergic burden.
People taking other anticholinergic drugs: The effects stack. If you are already on a medication with anticholinergic properties, such as certain antihistamines, bladder medications, or antidepressants, adding cyclobenzaprine can push your total anticholinergic load high enough to make constipation severe. This cumulative “anticholinergic burden” is something pharmacists track more carefully than most patients realize.
People with preexisting GI conditions: If you already have irritable bowel syndrome with constipation, slow-transit constipation, or a condition that affects gut motility, cyclobenzaprine can make things considerably worse. The systematic review of fibromyalgia treatments in patients who also had irritable bowel syndrome noted that higher-dose cyclobenzaprine produced the most adverse effects in that overlap population.⁴
People on opioids: Opioids are notorious for causing constipation through their own separate mechanism. Adding cyclobenzaprine to an opioid creates a double hit to gut motility. Muscle spasm from back pain is one of the most common reasons these two drugs end up prescribed together, and the combination can produce constipation severe enough to require medical intervention.

If any of those categories apply to you, it is especially important to have a plan for managing constipation before it becomes a problem rather than reacting after several uncomfortable days.

Practical Ways to Manage or Prevent It

The good news is that cyclobenzaprine-induced constipation is manageable for most people, particularly because the drug is usually prescribed for short courses of two to three weeks rather than indefinitely. A few strategies can make the difference between tolerable slowing and genuine misery.

Hydration is the most straightforward countermeasure. Anticholinergic drugs reduce fluid secretion throughout the digestive tract, and dry mouth is your body’s way of announcing that fluid balance has shifted. Drinking more water will not completely override the pharmacological effect, but it gives your colon more to work with. Fiber intake matters too, though with a caveat: adding fiber without adequate fluid can actually make things worse, creating bulkier stool that still moves slowly. The combination of both is what helps.

If dietary adjustments are not enough, over-the-counter options are reasonable. Osmotic laxatives like polyethylene glycol (the powder you stir into water) are generally the first choice because they work gently by drawing water into the bowel. Stimulant laxatives like senna or bisacodyl work faster but are better reserved for occasional use. Stool softeners like docusate are mild enough for daily use during a short course of cyclobenzaprine, and some clinicians will proactively recommend one if they know you are prone to constipation.

Physical activity, if your underlying muscle spasm allows it, also helps. Walking is one of the most effective non-pharmacological ways to keep the gut moving, and even gentle movement counteracts some of the sedentary effect that pain and drowsiness can impose while you are on cyclobenzaprine.

When Constipation Becomes a Concern

Most people who get constipated on cyclobenzaprine experience mild to moderate discomfort that resolves once they stop the drug or take basic preventive steps. But there is a line where constipation shifts from an annoyance to a medical concern. If you go more than three or four days without a bowel movement, develop significant abdominal bloating or pain, start vomiting, or notice blood in your stool, you should contact your prescriber. Severe, prolonged constipation can occasionally progress to fecal impaction, particularly in older adults or people on multiple constipating medications.

It is also worth knowing that the other anticholinergic effects of cyclobenzaprine, such as urinary retention, rapid heart rate, and confusion, tend to cluster together when the anticholinergic load gets high.⁵ If you are experiencing constipation alongside difficulty urinating, a noticeably fast pulse, or mental fogginess, the issue may not be just your gut. Those symptoms taken together suggest your overall anticholinergic burden is too high, and your prescriber should know about it.

The Dry Mouth and Constipation Cluster

People taking cyclobenzaprine often notice dry mouth and constipation arriving as a package deal, and that is not a coincidence. Both are downstream effects of the same acetylcholine blockade. Dry mouth tends to show up faster, sometimes within hours of the first dose, because salivary glands respond quickly to anticholinergic interference. Constipation takes a day or two longer to declare itself because the gut has more inertia. But if you have significant dry mouth, there is a reasonable chance your intestines are also being affected even before you notice a change in bowel habits.

This pairing can be useful as an early warning system. If your mouth feels like sandpaper within the first day of starting cyclobenzaprine, it is a signal to be proactive about hydration and fiber before constipation catches up. People who dismiss the dry mouth as a minor nuisance and do nothing about it often find themselves dealing with more stubborn constipation a few days later. The two symptoms share a remedy as well: drinking more fluid addresses both, at least partially.

Why Some People Feel Nothing at All

Anticholinergic sensitivity varies widely from person to person, and not everyone who takes cyclobenzaprine will notice any change in their bowel habits. Younger adults with robust gut motility and no preexisting constipation often sail through a short course with nothing more than mild drowsiness. The liver enzymes responsible for metabolizing cyclobenzaprine also vary in activity between individuals, meaning some people clear the drug faster and experience lower peak levels even at the same dose. Genetic differences in acetylcholine receptor density in the gut may also play a role, though this has not been studied specifically for cyclobenzaprine.

If you are prescribed cyclobenzaprine and you do not develop constipation, that does not mean you are immune to other anticholinergic effects or that the drug is not working. The absence of constipation simply reflects your particular physiology. Conversely, if you have had constipation from other anticholinergic medications in the past, whether antihistamines, bladder drugs, or tricyclic antidepressants, you are likely to experience it again with cyclobenzaprine, because the underlying mechanism is the same. Your previous response to any drug in that broad anticholinergic family is a reasonable predictor of what to expect.

Newer Formulations and Whether They Help

Pharmaceutical interest in cyclobenzaprine has not ended with the decades-old tablets. A sublingual formulation has been investigated for conditions like fibromyalgia, with the rationale that delivering the drug through the mucous membranes under the tongue changes how quickly it enters the bloodstream and may alter its side-effect profile. The idea is that a lower, more targeted dose absorbed sublingually could provide therapeutic benefit at the central nervous system level while producing less anticholinergic effect in the periphery, including the gut. Early data on this delivery method is still limited, and it remains unclear whether it meaningfully reduces constipation rates compared with oral tablets at equivalent therapeutic effect. For now, the standard oral formulation in immediate-release and extended-release versions remains the norm, and constipation management for most people comes down to dose selection, hydration, and short treatment courses rather than switching to an alternative delivery route.